AU2023217931A1 - Preparation for use in a method for the treatment and/or prevention of a disease - Google Patents

Preparation for use in a method for the treatment and/or prevention of a disease Download PDF

Info

Publication number
AU2023217931A1
AU2023217931A1 AU2023217931A AU2023217931A AU2023217931A1 AU 2023217931 A1 AU2023217931 A1 AU 2023217931A1 AU 2023217931 A AU2023217931 A AU 2023217931A AU 2023217931 A AU2023217931 A AU 2023217931A AU 2023217931 A1 AU2023217931 A1 AU 2023217931A1
Authority
AU
Australia
Prior art keywords
lipid
preparation
mol
group
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023217931A
Other languages
English (en)
Inventor
Volker Fehring
Jörg Kaufmann
Oliver Keil
Akanksha MOGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pantherna Therapeutics GmbH
Original Assignee
Pantherna Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantherna Therapeutics GmbH filed Critical Pantherna Therapeutics GmbH
Publication of AU2023217931A1 publication Critical patent/AU2023217931A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023217931A 2022-02-14 2023-02-14 Preparation for use in a method for the treatment and/or prevention of a disease Pending AU2023217931A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22156604.5A EP4226949A1 (en) 2022-02-14 2022-02-14 Preparation for use in a method for the treatment and/or prevention of a disease
EP22156604.5 2022-02-14
PCT/EP2023/053639 WO2023152398A1 (en) 2022-02-14 2023-02-14 Preparation for use in a method for the treatment and/or prevention of a disease

Publications (1)

Publication Number Publication Date
AU2023217931A1 true AU2023217931A1 (en) 2024-07-18

Family

ID=80683166

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023217931A Pending AU2023217931A1 (en) 2022-02-14 2023-02-14 Preparation for use in a method for the treatment and/or prevention of a disease

Country Status (8)

Country Link
US (1) US20240408014A1 (https=)
EP (2) EP4226949A1 (https=)
JP (1) JP2025505258A (https=)
KR (1) KR20240149887A (https=)
CN (1) CN118695875A (https=)
AU (1) AU2023217931A1 (https=)
CA (1) CA3243105A1 (https=)
WO (1) WO2023152398A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4681739A1 (en) 2024-07-19 2026-01-21 PROVIREX Genome Editing Therapies GmbH Lipid nanoparticles for direct delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119058A2 (en) * 2010-03-22 2011-09-29 Universidade De Coimbra F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases
JP2018509387A (ja) * 2015-01-21 2018-04-05 フェーズアールエックス インコーポレイテッド 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
US20180200186A1 (en) * 2015-07-09 2018-07-19 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
EP3562510A4 (en) * 2016-12-30 2021-01-06 Genevant Sciences GmbH BRANCHED PEG MOLECULES AND ASSOCIATED COMPOSITIONS AND PROCEDURES

Also Published As

Publication number Publication date
EP4226949A1 (en) 2023-08-16
WO2023152398A1 (en) 2023-08-17
EP4479096A1 (en) 2024-12-25
KR20240149887A (ko) 2024-10-15
CN118695875A (zh) 2024-09-24
JP2025505258A (ja) 2025-02-21
US20240408014A1 (en) 2024-12-12
CA3243105A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
JP7515914B2 (ja) 生体内薬物伝達のための脂質ナノ粒子およびその用途
CN101903018B (zh) 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法
KR102537540B1 (ko) 만노스를 포함하는 지질 나노입자 또는 이의 용도
EP2377517A2 (en) Pharmaceutical composition containing an anionic drug, and a production method therefor
JP2017165748A (ja) 薬物送達用の脂質ナノ粒子の生成方法
CN104582691A (zh) 脂膜白蛋白纳米颗粒组合物以及制备和使用其的方法
EP3349730B1 (en) Systems for nucleic acid expression in vivo
US20250099393A1 (en) Ionizable lipids, lipid nanoparticles, and uses thereof
Ita Dermal/transdermal delivery of small interfering RNA and antisense oligonucleotides-advances and hurdles
EP4626400A1 (en) Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
Xu et al. Ligands located within a cholesterol domain enhance gene delivery to the target tissue
WO2024086929A1 (en) Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
US20240408014A1 (en) Preparation for use in a method for the treatment and/or prevention of a disease
JP2024505924A (ja) 核酸送達
KR20240072931A (ko) 히스티딘을 포함하는 지질 나노입자 및 그 제조방법
WO2010067617A1 (ja) 脂質膜構造体
CN117460537A (zh) 核酸递送
KR102898792B1 (ko) 이온화 가능한 펩타이드를 이용한 지질 나노입자 기반 약물 전달체 및 이의 제조방법
RU2799045C1 (ru) Липидные наночастицы для доставки лекарственного средства in vivo и их применение
AU2024342003A1 (en) Delivery system and method of preparation thereof
KR20250092049A (ko) mRNA/LNP 백신의 면역원성 향상용 지질
AU2024356983A1 (en) Method of delivery of dna or rna cargo using unshielded lipid nanoparticles
WO2025073054A1 (en) Method of delivery of dna or rna cargo using unshielded lipid nanoparticles
WO2024250095A1 (en) An intelligent charge switchable polymer-lipid hybrid system for in vivo delivery of molecules including rnas
JP2024500515A (ja) 脂質ナノ粒子を含む癌の予防または治療用組成物